2022 International Congress Archives - Page 17 of 153

Identification and clinical characterization of GBA variants in the Luxembourg Parkinson’s Study

S. Pachchek, Z. Landoulsi, D. Reddy Bobbili, L. Pavelka, O. Terwindt, J. Torre, A K. Hauser, C. Schulte, E. Buena-Atienza, C. Gross, N. Casadei, R. Krüger, P. May (Belvaux, Luxembourg)
Identification and functional characterization of genetic modifier of penetrance in G2019S LRRK2-associated Parkinson’s disease through family whole genome sequencing

J. Ohnmacht, D. Bobbili, P. May, E. Glaab, J. Kaye, S. Finkbeiner, R. Krüger (Strassen, Luxembourg)
Identification of two novel patients with VPS13D-related disease and characterization of a +3 splice site variant

M. Pauly, N. Brüggemann, S. Efthymiou, H. Houlden, V. Chelban, F. Hinrichs, V. Tadic, A. Münchau, K. Lohmann (Lübeck, Germany)
Identifying meaningful symptoms and impacts of disease for patients with early Parkinson’s disease

J. Mammen, R. Speck, R. Dorsey, M. Müller, P. Yang, S. Jensen-Roberts, M. Kostrzebski, J. Cosman, J. Hellsten, J. Crawford, G. Stebbins, J. Cedarbaum, T. Simuni, T. Dam, K. Ward Barowicz, D. Stephenson, J. Adams (Providence, USA)
iFall: Usability of a co-produced falls reporting smartphone application in people with Parkinson’s

R. Morris, J. Moore, N. Ratcliffe, G. Barry, J. Naisby, A. Amjad, A. Godfrey, G. Standerline, E. Webster (Newcastle upon Tyne, United Kingdom)
IgG to neurotensin in blood of Parkinson’s disease patients

Z. Muruzheva, M. Absalyamova (Saint-Petersburg, Russian Federation)
IkT-148009 as a potential disease-modifying therapy in PD

M. Werner, S. Karuppagounder, R. Rush, T. Kelly, T. Dawson, V. Dawson (Atlanta, USA)
Illness perception in patients with Functional Movement Disorders: a case series

D. Campo-Caballero, L. Martínez, B. Martín, P. Rada, M. Kurtis, I. Pareés (San Sebastián, Spain)
Illusion of semi-inverted posture during High Frequency Ultrasound Stimulation thalamotomy for tremor

M. Ciocca, M. Mahmud, A. Jameel, W. Gedroyc, D. Nandi, Y. Tai, B. Seemungal, P. Bain (London, United Kingdom)
Illusory responses across the Lewy body disease spectrum

M. Shahid, A. Rawls, V. Ramirez, S. Ryman, V. Santini, L. Yang, S. Sha, J. Hall, T. Montine, A. Lin, L. Tian, V. Henderson, B. Cholerton, M. Yutsis, K. Poston (Palo Alto, USA)
Imaging progressive peripheral and central dysfunction in isolated REM sleep behaviour disorder after 3 years of follow-up

T. Fedorova, K. Knudsen, K. Andersen, J. Horsager, C. Skjærbæk, M. Otto, K. Svendsen, P. Borghammer (Aarhus N, Denmark)
Imaging Tau in Atypical Parkinsonisms: Meta-Analysis of in vivo PET Imaging Findings

A. Mena, A. Strafella (Toronto, Canada)
Impact of ApoE genotype on cognition in idiopathic and genetic forms of Parkinson’s disease

C. Koros, K. Brockmann, Aμ. Simitsi, A. Bougea, H. Liu, ακ. Hauser, C. Schulte, I. Pachi, N. Papagiannakis, A. Zahou, I. Wurster, E. Efthymiopoulou, I. Beratis, R. Antonelou, M. Maniati, M. Moraitou, H. Michelakakis, G. Paraskevas, S. Papageorgiou, C. Potagas, D. Papadimitriou, M. Bozi, M. Stamelou, T. Gasser, L. Stefanis (Athens, Greece)
Impact of botulinum toxin treatment on gait in focal dystonia

J. Cuinat, B. Debu, P. Pelissier, A. Castrioto, S. Meoni, S. Potel, V. Fraix, E. Moro (Grenoble, France)
IMPACT OF COVID 19 ON PARKINSON’S DISEASE: A CROSS SECTIONAL STUDY

G. Desai, T. Nanayakkara, G. Pun, A. Chatterjee, N. Butt (READING, United Kingdom)
Impact of COVID-19 in Parkinson disease: preliminary analysis from a survey performed in a Peruvian PD cohort.

E. Sarapura-Castro, D. Rivera-Asencios, M. Illanes-Manrique, A. Rivera-Valdivia, M. Inca-Martinez, K. Mejia-Rojas, J. Rios-Pinto, A. Medina-Colque, I. Cornejo-Herrera, E. Ochoa-Valle, C. Cosentino, I. Mata, M. Cornejo-Olivas (Lima, Peru)
Impact of DBS on cognitive functions in Parkinson’s disease in 1 year follow-up

A. Martinkovičová, Z. Košutzká, M. Pápayová, I. Straka, M. Kľoc, P. Valkovič (Bratislava, Slovakia)
IMPACT OF DEEP BRAIN STIMULATION ELECTRODE POSITION ON GAIT IN PATIENTS WITH PARKINSON’S DISEASE

J. Bardoň, D. Burďáková, J. Valošek, D. Krahulík, P. Otruba, P. Kaňovský, M. Nevrlý (Olomouc, Czech Republic)
Impact of dopamine replacement therapies on MDS-UPDRS II

F. Nassan, J. Shirvan, M. Yang, T. Dam, J. Wang, N. Maserejian, W. Flanders (Brookline, USA)
Impact of foslevodopa/foscarbidopa on key clinical and patient-reported outcomes in patients with aPD: Responder analysis of two Phase 3 clinical trials

M. Soileau, J. Aldred, A. Antonini, C. Carroll, V. Fung, T. Henriksen, R. Pahwa, D. Santos Garcia, A. Epstein, C. Yan, A. Alobaidi, A. Shewale, A. Spiegel, M. Facheris, J. Zamudio, P. Kukreja, KR. Chaudhuri (Georgetown, USA)
Impact of GBA Mutations in the Outcomes of Deep Brain Stimulation in Parkinson’s

M. Roque, R. Barbosa, P. Pita Lobo, A. Valadas, B. Cattoni, H. Carvalho, M. Rosa, J. Ferreira, M. Coelho, L. Guedes (Lisbon, Portugal)
Impact of istradefylline on the adjustment of levodopa dose escalation in Parkinson’s disease: Results of the ISTRA ADJUST PD randomized, controlled study

T. Hatano, O. Kano, R. Sengoku, N. Yanagisawa, H. Nagayama (Tokyo, Japan)
Impact of Nonmotor Symptoms on The Quality of Life of Parkinson’s Disease Patients

R. Nindela, O. Tambun, S. Marisdina, E. Bahar (Palembang, Indonesia)
Impact of rs6265 in the Host and Donor on Dopamine Neuron Graft Function.

C. Szarowicz, M. Caulfield, J. Stancati, M. Vanderwerp, C. Sortwell, J. Patterson, M. Benskey, T. Collier, K. Steece-Collier (Grand Rapids, USA)
Impact of SARS-CoV-2 vaccine in Parkinson’s disease

E. Reséndiz-Henríquez, E. Ichikawa-Escamilla, P. Bazán-Rodríguez, MA. Ruiz-Mafud, AJ. Hernández-Medrano, GI. Cerda-Hernández, RA. Abundes-Corona, A. Cervantes-Arriaga, M. Rodríguez-Violante (Mexico City, Mexico)
Impact of Th17 pathway-related immuno-inflammatory cytokines in the risk and severity of Parkinson’s Disease.

M. Debnath, M. Gothwal, N. Sreenivas, S. Dey, M. Thrinath, R. Yadav, PK. Pal, J. Saini (Bengaluru, India)
Impact of the delayed diagnosis in the prognosis of Parkinson’s disease.

E. Ichikawa-Escamilla, AJ. Hernández-Medrano, P. Bazán-Rodríguez, E. Reséndiz-Henríquez, GI. Cerda-Hernández, MA. Ruíz-Mafud, RA. Abundes-Corona, A. Cervantes-Arriaga, M. Rodríguez-Violante (Mexico City, Mexico)
Impact of the dopamine system on long-term, incident cognitive impairment in Parkinson disease

D. Weintraub, M. Picillo, H. Cho, C. Caspell-Garcia, C. Coffey, K. Marek, K. Poston, T. Simuni, J. Seibyl, A. Siderowf, A. Singleton, C. Tanner (Philadelphia, USA)
Impact of two different rechargeable pulse generators on parkinsonian patients with deep brain stimulation

C. Bogaert, C. Der Linden (Gent, Belgium)
Impact on non-motor symptoms, cognition, and QoL after 1-year of DBS for Parkinson’s Disease: An interim report from the ADROIT NAPA sub-study

M. Poetter-Nerger, S. Groppa, O. Adam, A. Schnitzler, M. Navas Garcia, B. Cheeran, L. Himes, M. Frassica, A. Gharabaghi (Hamburg, Germany)
Impaired behavioral proactive inhibitory control and flexibility in a mouse model of early Parkinson’s disease

J. Lhost, AM. Ouagazzal, M. Liberge, M. Amalric (Marseille, France)
Impaired Imagery of Tremor in Patients with Essential Tremor

K. Steidel, A R. Abou Watfa, C. Nelles, E. Pelzer, M. Tittgemeyer, L. Timmermann, DJ. Pedrosa (Marburg, Germany)
Impaired reinforcement learning in patients with cerebellar ataxia

J. Nicholas, CJ. Amlang, CY. Lin, N. Desai, L. Montaser-Kouhsari, SH. Kuo, D. Shohamy (New York, USA)
Implementing Team-Based Outpatient Palliative Care in Parkinson’s Foundation Centers of Excellence (COE): Study Design

M. Dini, S. Seshadri, S. Norton, J. Holtrop, P. Auinger, N. Yarab, B. Kluger (New York, USA)
Importance of lifestyle advice for participants in studies of early Parkinson’s disease

F. Fuchs, I. Tödt, A. Rogge, J. Naumann, D. Berg, E. Schäffer (Kiel, Germany)
Improvement of masticatory muscles’ pain versus tenderness via electromyography biofeedback training in patients with bruxism.

M. Amine, U. El-Dakrory (Mohandessine, Egypt)
Improvement of movement disorder and neurodevelopment under selegiline in a CLTC deficient patient

F. Nardecchia, L. Pannone, F. Manti, V. Muto, R. Bove, L. Pollini, M. Giannini, M. Tartaglia, S. Martinelli, V. Leuzzi (Rome, Italy)
Improving Dual Task Walking Control after Training with Internal-focus Strategy in Parkinson Disease with Freezing of Gait

SH. Yu, CY. Huang, CH. Sheu, RM. Wu, YC. Liao (Taipei, Taiwan)
Improving the design of clinical trials in early-stage Parkinson’s disease by using the estimand framework

J. Anzures-Cabrera, A. Monnet, G. Pagano (Welwyn Garden City, United Kingdom)
Improving the patient self-awareness of the first motor fluctuations in early Parkinson’s disease with a wearable sensor

N. Caballol, A. Pérez-Soriano, A. Planas-Ballvé, A. ávila, P. Quispe, A. Bayés (Sant Joan Despí, Spain)
Improving timely administration of PD meds in the hospital by using “custom” schedules

H. Azmi, F. Ruzicka, L. Cocoziello, J. Pederson, E. Clar, A. Rocco, F. Thomas (Oradell, USA)
Impulse control disorder following bilateral pallidothalamic tract focused ultrasound: a case report

S. Farrand, P. Phal, K. Fernando, A. Evans, R. Blaze (Richmond, Australia)
Impulse Control Disorders Following Bilateral Subthalamic Deep Brain Stimulation for Parkinson’s Disease: The INTREPID Randomized Controlled Trial

T. Stiep, A. Tröster, A. Ramirez-Zamora, R. Jain, L. Chen, M. Okun (Gainesville, USA)
In Silico Study Reveals Cocaine Exposure Modulates Dopamine Neuron Firing Patterns by Inhibiting Small Conductance Calcium Activated Potassium Current

CHI. Mahapatra (Mumbai, India)
in vivo and autopsy validation of alpha-synuclein seeding activity using RT-QuIC assay in the gastrointestinal tract of patients with Parkinson’s disease

C. Shin, JY. Han, YP. Choi, SI. Kim, SH. Park, HK. Yang, HJ. Lee, SH. Kong, YS. Suh, HJ. Kim, B. Jeon (Sejong-si, Republic of Korea)
In vivo synaptic density in parkinsonism

C. Uribe, KL. Desmond, R. Raymond, K. Smart, A. Reilhac, A. Mena, AE. Lang, G. Kovacs, N. Vasdev, AP. Strafella (Toronto, Canada)
In-home remote assessment of the MDS-UPDRS Part III: multi-cultural development and validation of a guide for patients and care partners

M. Tosin, A. Ferro, R. Wu, P. Rabano, P. Martinez-Martin, C. Goetz, G. Stebbins, T. Mestre (Chicago, USA)
In-vivo measurement of tau depositions in anti-IgLON5 disease with 18F-PI2620-PET

H. Theis, GN. Bischof, I. Ayzenberg, N. Brüggemann, T. Grüter, J. Hammes, J. Lewerenz, F. Leypoldt, A. Drzezga, T. van Eimeren (Cologne, Germany)
Incidental Lewy Body disease and idiopathic Parkinson’s disease: from common pathogenic factors to the overlapping clinical features

E. Sansa, T. Warner, E. Depablo Fernandez (London, United Kingdom)
IncobotulinumtoxinA for treating chronic sialorrhea due to Parkinson’s disease and other neurological conditions

W. Jost, F. Pagan (Wolfach, Germany)
IncobotulinumtoxinA to treat sialorrhea in Parkinson’s disease: a real-life study

B. Bergmans, N. Winter, V. Schotte, N. Sys, E. van Massenhove, H. Couckuyt, M. van Zandijcke (Bruges & Ghent, Belgium)
Increased alpha-synuclein level in primary macrophages derived from patients with Parkinson’s disease

A. Kopytova, M. Nikolaev, G. Baydakova, A. Izymchenko, D. Bogdanova, I. Miliukhina, A. Emelyanov, E. Zakharova, S. Pchelina (Gatchina, Russian Federation)
Increased Neutrophil to Lymphocyte Ratio Distinguish Parkinson’s Disease and Parkinson Plus Syndrome

IH. Kwak, HI. Ma, YE. Kim (Anyang, Republic of Korea)
Increased Prevalence of Thyroid Disease in Cervical Dystonia

L. Scorr, G. Kilic-Berkmen, A. Rosen, C. Yeo, J. Hanfelt, H. Jinnah (Atlanta, USA)
Inducing motor cortical plasticity in Parkinson’s Disease patients using subthalamic deep brain stimulation and repetitive transcranial magnetic stimulation

C. Rinchon, C. Gunraj, N. Drummond, T. Hoque, KHS. Chen, R. Chen (Toronto, Canada)
Inflammatory biomarkers in newly diagnosed patients with Parkinson’s disease

C. Pedersen, A. Ushakova, G. Alves, O-B. Tysnes, D. Aarsland, J. Lange, J. Maple-Grødem (Sandnes, Norway)
Inflammatory changes in subjects with de novo Parkinson’s disease

T. Yacoubian, A. Gerstenecker, Y. Fang, A. Amara, N. Stover, L. Ruffrage, C. Collette, R. Kennedy, Y. Zhang, H. Qin, E. Benveniste, J. Mcconathy, D. Standaert (Birmingham, USA)
Inflammatory microglial and astroglial phenotype associated with pathological alpha-synuclein inclusions in the substantia nigra

A. Stoll, M. Bensky, J. Patterson, C. Kemp, K. Steece-Collier, M. Hore, K. Luk, C. Sortwell (Grand Rapids, USA)
Influence of alcohol consumption on cognitive decline in Parkinson disease.

E. Ruiz-Fernández, J. Marín-Lahoz, J. Pagonabarraga, A. Horta-Barba, S. Martínez-Horta, H. Bejr-Kasem, I. Aracil-Bolaños, A. Campolongo, J. Kulisevsky (Zaragoza, Spain)
Influence of dopaminergig medication and subthalamic nucleus deep brain stimulation on impulsive decision making in Parkinson’s disease

JC. Baldermann, A. Nehs, H. Jergas, H. Dafsari, V. Visser-Vandewalle, T. Dembek, M. Barbe (Cologne, Germany)
Initial experience with levodopa-entacapone-carbidopa intestinal gel infusion (LECIG) for the management of advanced Parkinson’s disease in Slovenia

E. Pipan, N. Zupančič Križnar, L. Ocepek, R. Rajnar, M. Kramberger, M. Menih, Z. Pirtošek, M. Trošt (Ljubljana, Slovenia)
Initial Postmarketing Real World Experience with directSTIM™ DBS System: A Case Series

W. Polanski, S. Sobottka, V. Coenen, A. Frank, B. Falkenburger (Dresden, Germany)
Insights from skin biopsies: α-synuclein real-time quaking-induced conversion (RT-QuIC) in patients with Parkinson’s disease and multiple system atrophy

C. Panzer, J. Volkmann, C. Sommer, K. Doppler, A. Kuzkina (Würzburg, Germany)
Intensive Multimodal Rehabilitation Intervention for Moderately Advanced Parkinson’s Disease

P. Moondra, A. Di Rocco, L. Rubin, C. Claro, A. Persaud, M. Mccrossin, A. Hernandez, D. Barreto, K. Schlosser, E. Stack, P. Fischetti, J. Yu, D. Green, L. Ptarcinski, K. Greco, G. Fequiere, C. Francavilla, B. Rubin, M. Tursi, J. Colton (Manhasset, USA)
Intermediate cardiac denervation in early Parkinson’s disease

S-W. Yoo, J-S. Kim (Seoul, Republic of Korea)
Intermuscular coherence as a biomarker of subthalamic nucleus deep brain stimulation efficacy in Parkinson’s disease

S. Lagerweij, J. van Zijl, T. van Laar, D. Oterdoom, J. van Dijk, M. Tijssen, J. Elting (Groningen, Netherlands)
Internal globus pallidus deep brain stimulation in ACTB-related deafness-dystonia

D. Macias-Garcia, S. Jesús, A. Adarmes-Gomez, L. Muñoz-Delgado, F. Carrillo, P. Mir (Seville, Spain)
International Telemedicine during COVID-19 Pandemic in an Academic Movement Disorder Clinic

N. Beltre, I. Haq, C. Luca, J. Margolesky, H. Paul, C. Singer, D. Shpiner (Miami, USA)
Interventions to Improve Gait in Parkinson’s Disease: A Systematic Review of Randomised Controlled Trials and Network Meta-Analysis

V. Hvingelby, A. Glud, JC. Sørensen, Y. Tai, AS. Andersen, VE. Johnsen, E. Moro, N. Pavese (Aarhus N, Denmark)
Intestinal microbial dysbiosis promotes prebiotic-reversible inflammation in Parkinson’s disease

R. Manfready, D. Hall, C. Goetz, A. Keshavarzian (Chicago, USA)
Intrafamilial phenotypic variability of spastic paraplegia type 7: A Case Report

D. Shah-Zamora, M. Rosenbaum (Chicago, USA)
Intraoperative microelectrode recodings reveal functional structure of Globus Pallidus pars interna in dystonic patients

A. Kaymak, M. Vissani, S. Rinaldo, R. Eleopra, L. Romito, A. Mazzoni (Pisa, Italy)
Intraoperative quantification of MDS-UPDRS tremor measurements using 3D accelerometry

A. Smid, J. Elting, J. van Dijk, E. Otten, D. Oterdoom, K. Tamasi, T. Heida, T. van Laar, G. Drost (Groningen, Netherlands)
Investigating genetic risk factors for Lewy body dementia

J. Lee, S. Jo, S. Lee, MS. Kim, SJ. Chung (Seoul, Republic of Korea)
Investigating inflammatory mechanisms in iPSC-derived LRRK2 microglia

K. Badanjak, P. Mulica, P. Seibler, M. Ali, C. Venegas, S. Pereira, C. Klein, P. Antony, E. Glaab, A. Grünewald (Esch-Sur-Alzette, Luxembourg)
Investigating the use of DAT-SPECT as an enrichment biomarker to determine eligibility for the phase 2 clinical trial PASADENA

T. Kustermann, S. Holiga, S. Zanigni, H. Svoboda, T. Nikolcheva, G. Pagano, K. Taylor (Basel, Switzerland)
Investigation of Modifiers of β-Glucocerebrosidase in Cell Models of Parkinson’s Disease

A. Wernick, J. Evans, G. Virdi, M. Choi, D. Athauda, Z. Zanjani Shadman, H. Plun-Favreau, S. Wray, S. Gandhi (London, United Kingdom)
Investigative Study of Local Field Potential (LFP) changes during acute and chronic Deep Brain Stimulation (DBS) in Parkinson’s Disease (PD) patients

G. Varga, V. Rayudu, J. Abraham (Austin, USA)
Invisible DBS-lead fixation using a patient-specific burr-hole cover

L. Stieglitz (Zurich, Switzerland)
Involving people with lived experience of Parkinson’s in trial design: the EJS ACT-PD initiative

M-L. Zeissler, N. Bakshi, M. Bartlett, A. Batla, D. Byrom, R. Chapman, E. Deeson, R. Ellis-Doyle, C. Gonzales-Robles, A. Jewell, H. Matthews, L. Miller, G. Mills, L. Mooney, A. Morgan, J. Rudiger, D. Salathiel, P. Scurfield, C. Siu, S. Whipps, S. Wonnacott, T. Foltynie, C. Carroll, K. Mcfarthing (Plymouth, United Kingdom)
IPX203 dose conversion from immediate-release carbidopa-levodopa, in Parkinson’s disease patients with motor fluctuations.

R. Hauser, A. Espay, W. Ondo, B. Safirstein, H. Moore, R. Kumar, G. Banisadr, S. Fisher (Tampa, USA)
Is Increased Mineralisation of Putamen Relevant for Pathophysiology of Cervical Dystonia?

Z. Kosutzka, M. Jezberova, I. Straka, P. Valkovic (Bratislava, Slovakia)
Is left handedness associated with Parkinson’s disease? Evidence from the E3N cohort study and Mendelian randomization.

G. Pesce, PE. Sugier, C. Domenighetti, F. Artaud, T. Truong, E. Flamand-Roze, M. Canonico, A. Elbaz (Villejuif, France)
Is motor symptoms asymmetry a possible predictor of short-term motor outcome of bilateral STN-DBS in Parkinson’s disease?

F. Cavallieri, F. Bove, A. Castrioto, S. Meoni, E. Schmitt, A. Bichon, A. Kistner, P. Pélissier, E. Lhommée, E. Chevrier, S. Chabardès, E. Seigneuret, V. Fraix, E. Moro (Reggio Emilia, Italy)
Is there a role for safinamide in atypical parkinsonian syndromes?

A. Silva, M. Rodrigues (Braga, Portugal)
Isolated craniocervical dystonia without neuropsychiatric manifestations associated with NMDA-receptor antibodies

S. Waller, L. Williams, A. Lee, MW. Lin, H. Morales-Briceno, V. Fung (Westmead, Australia)
Isolated ZIC4 antibody associated paraneoplastic cerebellar degeneration

A. Agarwal, A. Garg, A. Srivastava (New Delhi, India)
It takes a village: An interdisciplinary care model for atypical Parkinsonism

H. Glover, J. Shurer, M. Ivancic, M. Sklerov (Chapel Hill, USA)